Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.64 |
| ▸ | HPGD | P15428 | 10/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.64 |
| ▸ | LMNA | P02545 | 7/20 | 0.64 |
| ▸ | TSHR | P16473 | 7/20 | 0.64 |
| ▸ | TP53 | P04637 | 6/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | HTT | P42858 | 5/20 | 0.50 |
| ▸ | CASP1 | P29466 | 3/20 | 0.50 |
| ▸ | CASP7 | P55210 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4778232 | 0.93 | TP53 (0.61) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL4725736 | 0.90 | LMNA (0.62) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL4796199 | 0.90 | HPGD (0.64) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL4940751 | 0.87 | HSD17B10 (0.60) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL4940985 | 0.86 | ALDH1A1 (0.64) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL4780930 | 0.85 | LMNA (0.64) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL4795515 | 0.85 | KDM4E (0.65) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL4725441 | 0.84 | KDM4E (0.62) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL4939020 | 0.84 | ALDH1A1 (0.62) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL4777718 | 0.84 | ALDH1A1 (0.54) | KDM4EALDH1A1HPGDHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221129-A1 | New compounds | BIOVITRUM AB (PUBL) (SE) | 2008-09-11 | — | — | US | claimed |
| WO-2008003753-A1 | PYRAZOLO [1,5-A] PYRIMIDINE ANALOGS FOR USE AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) ACTIVITY | BIOVITRUM AB (PUBL) (SE) | 2008-01-10 | — | — | WO | claimed |
| EP-1999119-A2 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | Abbott Laboratories (US) | 2008-12-10 | — | — | EP | disclosed |
| US-20080221129-A1 | New compounds | BIOVITRUM AB (PUBL) (SE) | 2008-09-11 | — | — | US | disclosed |
| WO-2008003753-A1 | PYRAZOLO [1,5-A] PYRIMIDINE ANALOGS FOR USE AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) ACTIVITY | BIOVITRUM AB (PUBL) (SE) | 2008-01-10 | — | — | WO | disclosed |
| WO-2007095602-A2 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBOTT LABORATORIES (US) | 2007-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221129-A1 | New compounds | SCD, SCD5, FASN | KDM4E 3813/4885ALDH1A1 858/4885HPGD 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.